Valneva (NASDAQ:VALN) Stock Price Down 3.3%

Valneva SE (NASDAQ:VALN)’s share price was down 3.3% during trading on Thursday . The company traded as low as $7.33 and last traded at $7.33. Approximately 1,445 shares were traded during trading, a decline of 85% from the average daily volume of 9,585 shares. The stock had previously closed at $7.58.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Valneva in a report on Wednesday, August 14th.

Valneva Price Performance

The stock has a market cap of $509.76 million, a PE ratio of -17.95 and a beta of 2.20. The company has a current ratio of 2.63, a quick ratio of 2.15 and a debt-to-equity ratio of 0.97. The business has a fifty day simple moving average of $7.39 and a two-hundred day simple moving average of $7.68.

Valneva (NASDAQ:VALN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Valneva had a negative net margin of 21.31% and a negative return on equity of 20.01%. The business had revenue of $40.97 million during the quarter, compared to analyst estimates of $46.83 million. Research analysts forecast that Valneva SE will post 0.02 earnings per share for the current year.

Institutional Investors Weigh In On Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC lifted its holdings in Valneva SE (NASDAQ:VALN) by 42.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 88,252 shares of the company’s stock after buying an additional 26,248 shares during the period. AlphaCentric Advisors LLC owned about 0.13% of Valneva worth $649,000 at the end of the most recent reporting period. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.